Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers

Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers

Study Overview

• Status: Completed
• Conditions: Healthy Adult Male and Female Volunteers
• Intervention / Treatment: Drug: Exenatide; Drug: Palonosetron; Drug: Placebo; Drug: Moxifloxacin

Detailed Description

This single-center Phase I study will consist of 2 parts, a Pilot Part and a Core Part.

The Pilot Part of the study will be an open-label, non-randomized, single-treatment design in 10 healthy male and female subjects to determine if an infusion regimen of a 6-h continuous IV infusion of exenatide will lead to a mean plasma steady state concentration of 500 pg/mL.

The Core part of the study will be a double-blind (except for the use of open label active control moxifloxacin), randomized, placebo-controlled,3 period, 6-sequence, cross-over design in 72 healthy male and female subjects to evaluate whether exenatide at therapeutic and supra-therapeutic concentrations has a pharmacological effect on cardiac repolarization (threshold value >10 msec).

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands
    • PRA-Groningen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Body mass index (BMI) between 19 to 35 kg/m2 inclusive.
• Women of child bearing potential - use of an additional adequate method of contraception during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermacide.
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), and bilirubin within normal range at Screening.
• Fasting triglycerides within the normal range at Screening

Exclusion Criteria:

• History of type 1 or type 2 diabetes, or history of hypoglycemia.
• History or evidence of myocardial infarction, congestive heart failure, syncope not related to heart arrhythmia, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke or TIA.
• History of atrial fibrillation, flutter, or non-sustained or sustained VT.
• Personal or family history of sudden death or long QT syndrome.
• History of uncontrolled hypertension.
• History or evidence of acute or chronic pancreatitis.
• History of liver disease.
• Abnormal renal function.
• History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
• Thyroid-stimulating hormone (TSH) outside of normal limits at Screening .
• Weight loss surgery.
• History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for greater than 5 years may be included.)
• History of active alcohol within 1 year prior to Screening.
• History of drug abuse within 5 years prior to Screening or a positive prestudy drug screen.
• Weekly consumption of more than 14 alcoholic beverages for females and more than 21 alcoholic beverages for males.
• Smoke more than 10 cigarettes per day.
• Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
• History of hypersensitivity to any of the medications used in this study.
• Women that are pregnant, lactating, or planning to become pregnant.
• History of or positive results on screening tests for hepatitis B and/or hepatitis C and/or human immunodeficiency virus (HIV).
• History or evidence of immunocompromised status.
• Prior or current treatment with any GLP-1 receptor agonist (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650 clinical trial.
• Any gastrointestinal complaints within 7 days prior to first dosing.
• Use of medications within 14 days of first dose other than hormone replacement therapy and oral contraceptives.
• Chronic (8 consecutive days or greater) treatment with systemic corticosteroids.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: IV exenatide - pilot study; IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.	Drug: Exenatide; 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).; Drug: Palonosetron; 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Experimental: Treatment Group A - core study; IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.	Drug: Exenatide; 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).; Drug: Palonosetron; 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Experimental: Treatment Group B - core study; IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.	Drug: Palonosetron; 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide; Drug: Placebo; 6 hour IV infusion.
Experimental: Treatment Group C - core study; IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.	Drug: Palonosetron; 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide; Drug: Placebo; 6 hour IV infusion.; Drug: Moxifloxacin; 400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Pilot Study: Establishment of mean plasma steady state concentration of 500 pg/mL	35 days
Core Study: Changes to QTc interval changes (threshold > 10 msec) measurements	56 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pilot Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs		35 days
Core Study: Measurement of exenatide plasma concentrations and relationship to changes in QTc interval measurements	Relationship between plasma concentrations of exenatide and QTc interval.	56 days
Core Study: Changes in PR, RR, QRS, QT, T- and U- wave morphology		56 days
Core Study: Measurement of QTc interval changes moxifloxacin as active control		56 days
Core Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs		56 days
Pilot Study: Maximum concentration (CMax) of exenatide		35 days
Pilot Study: Time to maximum concentration (TMax) of exenatide		35 days
Pilot Study: Area under the curve (AUC) of exenatide		35 days
Pilot Study: Steady state concentration (Css) of exenatide		35 days
Pilot Study: Half life (T1/2) of exenatide		35 days
Core Study: Half life (T1/2) of exenatide		56 days
Core Study: Steady state concentration (Css) of exenatide		56 days
Core Study: Area under the curve (AUC) of exenatide		56 days
Core Study: Maximum concentration (CMax)		56 days
Core Study: Time to maximum concentration (TMax) of exenatide		56 days

Collaborators and Investigators

• Sponsor: Intarcia Therapeutics

Study record dates

Study Major Dates

• Study Start: January 1, 2016
• Primary Completion (Actual): April 1, 2016
• Study Completion (Actual): April 1, 2016

Study Registration Dates

• First Submitted: January 1, 2016
• First Submitted That Met QC Criteria: January 6, 2016
• First Posted (Estimate): January 8, 2016

Study Record Updates

• Last Update Posted (Estimate): January 27, 2017
• Last Update Submitted That Met QC Criteria: January 26, 2017
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hypoglycemic Agents; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Serotonin Agents; Serotonin Antagonists; Serotonin 5-HT3 Receptor Antagonists; Anti-Obesity Agents; Incretins; Palonosetron; Moxifloxacin; Exenatide
• Other Study ID Numbers: ITCA-650-CLP-114

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No